At the news
? NEUTRALIMPACT 2/10 144 filed Aug 14, 2026 at 17:21 ET
Director Dino A. Rossi filed a Form 144 notice of intent to sell 25,000 shares of Krystal Biotech common stock through Goldman Sachs, with an estimated aggregate market value of approximately $8.3 million based on the filing date. This represents about 0.08% of the company's $9.7B market cap and a modest portion of Rossi's total holdings of ~29.6 million shares. The sale is routine for a director and does not signal insider concern given the small proportional size and the company's strong institutional support (89% analyst bullish).
- Director Dino A. Rossi filed Form 144 to sell 25,000 shares of KRYS common stock.
- Estimated aggregate market value of the proposed sale is approximately $8.3 million.
- Rossi holds approximately 29.6 million shares post-sale, making this a ~0.08% reduction in his position.
- The shares were acquired from the public market on 09/22/2017, indicating long-term holding.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access